KR20010083134A - 아테롬성 동맥경화증 병소의 치료를 위한 acat 및mmp 억제제의 병용 투여 - Google Patents

아테롬성 동맥경화증 병소의 치료를 위한 acat 및mmp 억제제의 병용 투여 Download PDF

Info

Publication number
KR20010083134A
KR20010083134A KR1020017000930A KR20017000930A KR20010083134A KR 20010083134 A KR20010083134 A KR 20010083134A KR 1020017000930 A KR1020017000930 A KR 1020017000930A KR 20017000930 A KR20017000930 A KR 20017000930A KR 20010083134 A KR20010083134 A KR 20010083134A
Authority
KR
South Korea
Prior art keywords
acid
methyl
phenyl
biphenyl
hydroxy
Prior art date
Application number
KR1020017000930A
Other languages
English (en)
Korean (ko)
Inventor
토마스 마이클 앤드류 보칸
Original Assignee
로즈 암스트롱, 크리스틴 에이. 트러트웨인
워너-램버트 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로즈 암스트롱, 크리스틴 에이. 트러트웨인, 워너-램버트 캄파니 filed Critical 로즈 암스트롱, 크리스틴 에이. 트러트웨인
Publication of KR20010083134A publication Critical patent/KR20010083134A/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Indole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
KR1020017000930A 1998-07-21 1999-06-18 아테롬성 동맥경화증 병소의 치료를 위한 acat 및mmp 억제제의 병용 투여 KR20010083134A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
US60/093,639 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
KR20010083134A true KR20010083134A (ko) 2001-08-31

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017000930A KR20010083134A (ko) 1998-07-21 1999-06-18 아테롬성 동맥경화증 병소의 치료를 위한 acat 및mmp 억제제의 병용 투여

Country Status (25)

Country Link
EP (1) EP1098662A2 (cs)
JP (1) JP2002521328A (cs)
KR (1) KR20010083134A (cs)
CN (1) CN1310629A (cs)
AP (1) AP2001002035A0 (cs)
AU (1) AU4701799A (cs)
BG (1) BG105162A (cs)
BR (1) BR9912296A (cs)
CA (1) CA2335062A1 (cs)
CZ (1) CZ2001126A3 (cs)
EA (1) EA200100153A1 (cs)
EE (1) EE200100046A (cs)
HR (1) HRP20010055A2 (cs)
HU (1) HUP0102880A3 (cs)
ID (1) ID30030A (cs)
IL (1) IL140982A0 (cs)
IS (1) IS5809A (cs)
NO (1) NO20010291L (cs)
OA (1) OA11584A (cs)
PL (1) PL346011A1 (cs)
SK (1) SK502001A3 (cs)
TR (1) TR200100205T2 (cs)
WO (1) WO2000004892A2 (cs)
YU (1) YU3501A (cs)
ZA (1) ZA200100294B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1210401A (en) * 1999-11-05 2001-06-06 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
AU2268301A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel urea compounds, compositions and methods of use and preparation
KR20030029871A (ko) * 2000-09-01 2003-04-16 상꾜 가부시키가이샤 의약 조성물
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
DE60321775D1 (de) * 2002-04-03 2008-08-07 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
US7691843B2 (en) * 2002-07-11 2010-04-06 Pfizer Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
WO2016113713A1 (en) * 2015-01-15 2016-07-21 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
HUP9900668A3 (en) * 1995-08-04 2000-08-28 Warner Lambert Co Use of sulfamic acid derivatives, n-acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
KR20000011095A (ko) * 1996-05-17 2000-02-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 비페닐술폰아미드 매트릭스 메탈로프로테이나아제 억제제
BR9711988A (pt) * 1996-09-04 1999-08-24 Warner Lambert Co Inibidores de metaloproteinase de matriz e seus empregos terap-uticos

Also Published As

Publication number Publication date
EA200100153A1 (ru) 2001-08-27
HUP0102880A2 (en) 2002-06-29
HRP20010055A2 (en) 2002-04-30
YU3501A (sh) 2005-06-10
HUP0102880A3 (en) 2002-11-28
EE200100046A (et) 2002-06-17
ID30030A (id) 2001-11-01
PL346011A1 (en) 2002-01-14
WO2000004892A2 (en) 2000-02-03
BR9912296A (pt) 2001-04-17
AP2001002035A0 (en) 2001-03-31
NO20010291D0 (no) 2001-01-18
OA11584A (en) 2004-07-20
TR200100205T2 (tr) 2001-05-21
CA2335062A1 (en) 2000-02-03
AU4701799A (en) 2000-02-14
EP1098662A2 (en) 2001-05-16
NO20010291L (no) 2001-01-18
BG105162A (en) 2001-12-29
IS5809A (is) 2001-01-12
IL140982A0 (en) 2002-02-10
CZ2001126A3 (cs) 2002-01-16
JP2002521328A (ja) 2002-07-16
SK502001A3 (en) 2002-06-04
CN1310629A (zh) 2001-08-29
WO2000004892A3 (en) 2000-05-18
ZA200100294B (en) 2002-01-10

Similar Documents

Publication Publication Date Title
AU741768B2 (en) Method for treating and preventing heart failure and ventricular dilatation
EP1047450B1 (en) Ace inhibitor-mmp inhibitor combinations
AU737117B2 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
KR20010083134A (ko) 아테롬성 동맥경화증 병소의 치료를 위한 acat 및mmp 억제제의 병용 투여
US20020049237A1 (en) Statin-MMP inhibitor combinations
KR20010041916A (ko) 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제
US20050020607A1 (en) Statin-MMP inhibitor combinations
MXPA01000780A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
EP1366765A1 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
MXPA00003736A (en) Ace inhibitor-mmp inhibitor combinations
MXPA99002254A (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
AU2003248291A1 (en) Statin-matrix metalloproteinase inhibitor combinations
MXPA00005034A (en) Statin-matrix metalloproteinase inhibitor combinations

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid